{
    "nctId": "NCT02256670",
    "briefTitle": "Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial",
    "officialTitle": "Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial: Efficacy of a Text-messaging Application in Increasing Adherence With Adjuvant Endocrine Therapy for Stage I-III Hormone Receptor Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Patient Acceptance of Text Message Program",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically confirmed stage I-III, estrogen and/or progesterone receptor positive, as defined by ASCO-CAP guidelines, invasive breast cancer for whom adjuvant hormonal therapy is indicated following standard NCCN practice guidelines\n* Patients may enter the study before or within one month of starting endocrine treatment\n* Patients with synchronous bilateral breast cancers are eligible if both tumors are hormone receptor positive\n* Patient must be able to provide informed consent and agree to:\n* Complete questionnaires according to the pre-specified study design\n* Own a personal cell phone, agree to receive text messages on a monthly basis (including any costs), and share their personal cell phone number to receive text message reminder\n* sign consent to allow research staff to contact their pharmacies to determine prescription refill dates\n\nExclusion Criteria:\n\n* Patients with ductal carcinoma in situ",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}